Your browser doesn't support javascript.
loading
Prognostic impact of osteosarcopenia in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel.
Takeda, Tsuyoshi; Sasaki, Takashi; Okamoto, Takeshi; Ishitsuka, Takahiro; Yamada, Manabu; Nakagawa, Hiroki; Mie, Takafumi; Furukawa, Takaaki; Kasuga, Akiyoshi; Matsuyama, Masato; Ozaka, Masato; Sasahira, Naoki.
Afiliação
  • Takeda T; Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: tsuyoshi.takeda@jfcr.or.jp.
  • Sasaki T; Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: sasakit-tky@umin.ac.jp.
  • Okamoto T; Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: takeshi.okamoto@jfcr.or.jp.
  • Ishitsuka T; Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: takahiro.ishitsuka@jfcr.or.jp.
  • Yamada M; Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: manabu.yamada@jfcr.or.jp.
  • Nakagawa H; Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: hiroki.nakagawa@jfcr.or.jp.
  • Mie T; Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: takafumi.mie@jfcr.or.jp.
  • Furukawa T; Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: takaaki.furukawa@jfcr.or.jp.
  • Kasuga A; Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: akiyoshi.kasuga@jfcr.or.jp.
  • Matsuyama M; Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: masato.matsuyama@jfcr.or.jp.
  • Ozaka M; Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: masato.ozaka@jfcr.or.jp.
  • Sasahira N; Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: naoki.sasahira@jfcr.or.jp.
Pancreatology ; 23(3): 275-282, 2023 Apr.
Article em En | MEDLINE | ID: mdl-36792473
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Gencitabina Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Pancreatology Assunto da revista: ENDOCRINOLOGIA / GASTROENTEROLOGIA Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Gencitabina Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Pancreatology Assunto da revista: ENDOCRINOLOGIA / GASTROENTEROLOGIA Ano de publicação: 2023 Tipo de documento: Article